Fluorometholone
Flarex, Fluorometholone, Fml, Fml-s, Tobrasone (fluorometholone) is a small molecule pharmaceutical. Fluorometholone was first approved as Oxylone on 1982-01-01. It is used to treat conjunctivitis, inflammation, and keratitis in the USA. The pharmaceutical is active against glucocorticoid receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| eye diseases | D005128 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Flarex, Fluorometholone, Fml (discontinued: Fluor-op, Fml, Oxylone)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Fluorometholone
Fluorometholone
+
Sulfacetamide sodium
Fluorometholone acetate
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| flarex | New Drug Application | 2023-10-10 |
| fluorometholone | NDA authorized generic | 2020-09-24 |
| fluorometholone ophthalmic suspension | ANDA | 2024-01-09 |
| fml | New Drug Application | 2023-12-15 |
| fml forte | New Drug Application | 2023-12-15 |
| fml-s | 2007-02-20 |
Indications
FDA
EMA
Show 8 more
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
FLUOROMETHOLONE, FLUOROMETHOLONE, AMNEAL | |||
| 2024-07-07 | CGT | ||
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C05: Vasoprotectives
— C05A: Agents for treatment of hemorrhoids and anal fissures for topical use
— C05AA: Corticosteroids, topical for treatment of hemorrhoids and anal fissures
— C05AA06: Fluorometholone
D: Dermatologicals
— D07: Corticosteroids, dermatological preparations
— D07A: Corticosteroid dermatological preparations, plain
— D07AB: Corticosteroids, moderately potent (group ii)
— D07AB06: Fluorometholone
— D07C: Corticosteroids, combinations with antibiotics
— D07CB: Corticosteroids, moderately potent, combinations with antibiotics
— D07CB03: Fluorometholone and antibiotics
— D07X: Corticosteroids, other combinations
— D07XB: Corticosteroids, moderately potent, other combinations
— D07XB04: Fluorometholone
— D10: Anti-acne preparations
— D10A: Anti-acne preparations for topical use
— D10AA: Corticosteroids, combinations for treatment of acne
— D10AA01: Fluorometholone
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01B: Antiinflammatory agents, ophthalmologic
— S01BA: Corticosteroid ophthalmologic antiinflammatory agents, plain
— S01BA07: Fluorometholone
— S01BB: Corticosteroids and mydriatics in combination
— S01BB03: Fluorometholone and mydriatics
— S01C: Antiinflammatory agents and antiinfectives in combination
— S01CA: Corticosteroids and antiinfectives in combination, opthalmologic
— S01CA07: Fluorometholone and antiinfectives
— S01CB: Corticosteroids/antiinfectives/mydriatics in combination
— S01CB05: Fluorometholone
HCPCS
No data
Clinical
Clinical Trials
32 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dry eye syndromes | D015352 | — | H04.12 | — | — | 1 | 3 | 5 | 9 |
| Keratoconjunctivitis sicca | D007638 | EFO_1000906 | — | — | — | 1 | 1 | 5 | 7 |
| Intraocular pressure | D007429 | — | — | — | — | 1 | 3 | — | 4 |
| Keratoconjunctivitis | D007637 | — | H16.2 | — | — | 1 | 1 | — | 2 |
| Glaucoma | D005901 | EFO_0000516 | H40 | — | — | 1 | 1 | — | 2 |
| Corneal opacity | D003318 | HP_0007957 | — | — | 1 | 1 | 1 | — | 2 |
| Fuchs' endothelial dystrophy | D005642 | EFO_0003946 | H18.51 | — | 1 | — | 1 | — | 2 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | 2 | — | 2 |
| Infectious keratoconjunctivitis | D007639 | — | — | — | — | — | 1 | — | 1 |
| Strabismus | D013285 | HP_0000486 | H50.2 | — | — | — | 1 | — | 1 |
Show 9 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Eye diseases | D005128 | EFO_0003966 | H44 | — | — | 2 | — | 1 | 3 |
| Trichiasis | D058457 | HP_0001128 | — | — | — | 1 | — | 1 | 2 |
| Uveitis | D014605 | HP_0000554 | H20.9 | — | — | 1 | — | — | 1 |
| Anterior uveitis | D014606 | EFO_1000811 | — | — | — | 1 | — | — | 1 |
| Iridocyclitis | D015863 | HP_0001094 | H20 | — | — | 1 | — | — | 1 |
| Fibrosis | D005355 | — | — | — | — | 1 | — | — | 1 |
| Trabeculectomy | D014130 | — | — | — | — | 1 | — | — | 1 |
| Eyelid diseases | D005141 | EFO_0009547 | H02.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lacrimal apparatus diseases | D007766 | HP_0009926 | H04 | — | 1 | — | — | — | 1 |
| Corneal neovascularization | D016510 | EFO_1000880 | H16.4 | 1 | 1 | — | — | — | 1 |
| Pathologic neovascularization | D009389 | — | — | 1 | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pathologic dilatation | D004108 | — | — | — | — | — | — | 3 | 3 |
| Keratoconus | D007640 | EFO_0004223 | H18.6 | — | — | — | — | 3 | 3 |
| Regeneration | D012038 | — | — | — | — | — | — | 3 | 3 |
| Sjogren's syndrome | D012859 | EFO_0000699 | M35.0 | — | — | — | — | 2 | 2 |
| Syndrome | D013577 | — | — | — | — | — | — | 2 | 2 |
| Pterygium | D011625 | — | H11.0 | — | — | — | — | 1 | 1 |
| Descemet stripping endothelial keratoplasty | D057111 | — | — | — | — | — | — | 1 | 1 |
| Trachoma | D014141 | — | A71 | — | — | — | — | 1 | 1 |
| Corneal ulcer | D003320 | — | H16.0 | — | — | — | — | 1 | 1 |
| Ulcer | D014456 | MPATH_579 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Fluorometholone |
| INN | fluorometholone |
| Description | Fluorometholone is a member of the class of glucocorticoids that is Delta(1)-progesterone substituted at positions 11beta and 17 by hydroxy groups, at position 6alpha by a methyl group and at position 9 by a fluoro group. Used for the treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe. It has a role as an anti-inflammatory drug. It is a fluorinated steroid, an 11beta-hydroxy steroid, a 20-oxo steroid, a 3-oxo-Delta(1),Delta(4)-steroid, a glucocorticoid, a 17alpha-hydroxy steroid and a tertiary alpha-hydroxy ketone. It is functionally related to a Delta(1)-progesterone. |
| Classification | Small molecule |
| Drug class | steroids (not prednisolone derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C |
Identifiers
| PDB | — |
| CAS-ID | 426-13-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200600 |
| ChEBI ID | 31625 |
| PubChem CID | 9878 |
| DrugBank | DB00324 |
| UNII ID | SV0CSG527L (ChemIDplus, GSRS) |
Target
Agency Approved
NR3C1
NR3C1
Organism
Homo sapiens
Gene name
NR3C1
Gene synonyms
GRL
NCBI Gene ID
Protein name
glucocorticoid receptor
Protein synonyms
Nuclear receptor subfamily 3 group C member 1, nuclear receptor subfamily 3 group C member 1 variant hGR-B(54), nuclear receptor subfamily 3 group C member 1 variant hGR-B(77), nuclear receptor subfamily 3 group C member 1 variant hGR-B(93), nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
Uniprot ID
Mouse ortholog
Nr3c1 (14815)
glucocorticoid receptor (Q61629)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Fluorometholone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,292 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,032 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use